Evidence map›Paper›PMID 24472191›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2014

Alloprimed CD8(+) T cells regulate alloantibody and eliminate alloprimed B cells through perforin- and FasL-dependent mechanisms.

J M Zimmerer, T A Pham, C L Wright, K J Tobin, P B Sanghavi, S M Elzein, V M Sanders, G L Bumgardner

Open access · hybridAbstract read
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Antibody-suppressor CXCR5American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022
    Article
  6. CXCR5Journal of immunology (Baltimore, Md. : 1950) · 2021
    Review
  7. Article
  8. Experimental modeling of desensitization: What have we learned about preventing AMR?American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020
    Review
  9. Review
  10. Future prospects for CD8Immunological reviews · 2019
    Review
  11. Article
  12. Hepatocyte-induced CD4Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2018
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Immunological aspects of liver cell transplantation.World journal of transplantation · 2016
    Review
  19. Critical role of NKT cells in posttransplant alloantibody production.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2014
    Article
  20. CD8Immunology and cell biology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

J M ZimmererDepartment of Surgery, Comprehensive Transplant Center, The Ohio State University Wexner Medical Center, Columbus, OH.
T A Pham
C L Wright
K J Tobin
P B Sanghavi
S M Elzein
V M Sanders
G L Bumgardner
The Ohio State University Wexner Medical Center · USThe Ohio State University · US

Funding

Novel Mechanisms Regulating Posttransplant Humoral AlloimmunityR01AI083456 · NIAID · OHIO STATE UNIVERSITY · PI BUMGARDNER, GINNY L · 2011 to 2014
$1.5M
CD8+ T cell regulation of alloantibody production following transplantationF32DK082148 · NIDDK · OHIO STATE UNIVERSITY · PI ZIMMERER, JASON M. · 2009 to 2010
$97k
NIAID NIH HHS AI083456NIAID NIH HHS R01 AI083456NIDDK NIH HHS DK082148NIDDK NIH HHS F32 DK082148
6 · The paper itself

Abstract

While it is well known that CD4(+) T cells and B cells collaborate for antibody production, our group previously reported that CD8(+) T cells down-regulate alloantibody responses following transplantation. However, the exact mechanism involved in CD8(+) T cell-mediated down-regulation of alloantibody remains unclear. We also reported that alloantibody production is enhanced when either perforin or FasL is deficient in transplant recipients. Here, we report that CD8(+) T cell-deficient transplant recipient mice (high alloantibody producers) exhibit an increased number of primed B cells compared to WT transplant recipients. Furthermore, CD8(+) T cells require FasL, perforin and allospecificity to down-regulate posttransplant alloantibody production. In vivo CD8-mediated clearance of alloprimed B cells was also FasL- and perforin-dependent. In vitro data demonstrated that recipient CD8(+) T cells directly induce apoptosis of alloprimed IgG1(+) B cells in co-culture in an allospecific and MHC class I-dependent fashion. Altogether these data are consistent with the interpretation that CD8(+) T cells down-regulate posttransplant alloantibody production by FasL- and perforin-dependent direct elimination of alloprimed IgG1(+) B cells.

Indexed as

AnimalsAntibody FormationBlotting, WesternB-LymphocytesCD8-Positive T-LymphocytesCells, CulturedFas Ligand ProteinFlow CytometryHepatocytesImmunoglobulin GIsoantibodiesLiver TransplantationMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicFas Ligand ProteinImmunoglobulin GIsoantibodiesPerforinTumor Necrosis Factor-alphaAlloantibodyB cellsCD8+ T cellsFasLPerforin

Identifiers

PMID24472191
PMCPMC4018729
OpenAlexW1551076114

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.